Gilead Sciences, Second Genome ink collaboration strategic deal in biomarker and inflammatory bowel disease drug discovery
Gilead Sciences, Inc and Second Genome, a leader in microbiome science, announced that the companies have entered into a four-year strategic collaboration... Read More
CODA Biotherapeutics acquired 3 clinical stage assets from Attenua
CODA Biotherapeutics, a preclinical-stage biopharmaceutical company developing a gene therapy-mediated chemogenetic platform, announced it has completed the acquisition of Attenua, Inc. With... Read More
GSK to disinvest Rabipur and Encepur – vaccine for USD 1.1 billion
Posted on22 Oct 2019
Comments0
GlaxoSmithKline (GSK) will sell two travel vaccines to Bavarian Nordic for up to 955 million euros ($1.1 billion), the British firm said... Read More
Prometheus Biosciences collaboration deal with Takeda for targeted therapies for IBD
Posted on06 Oct 2019
Tagscodevelopment deal in pharma, pharma strategic deal, Prometheus Biosciences, Strategic deal in pharma, Takeda
Comments0
Prometheus Biosciences, Inc, a biopharmaceutical company, has entered into a global, multi-target strategic collaboration with Takeda Pharmaceutical Company Limited (Takeda) to discover,... Read More
Clovis in-licensing deal for cancer program from 3B Pharmaceuticals
Clovis Oncology inks an agreement with privately held 3B Pharmaceuticals GmbH for global rights (ex. Europe, Russia, Turkey and Israel) to a... Read More
Sumitomo Dainippon and Roivant’s strategic alliance to develop new medicine
Posted on08 Sep 2019
Comments0
Sumitomo Dainippon Pharma Co, Ltd, a leading Japanese pharmaceutical company, and Roivant Sciences Ltd, a technology-enabled healthcare company, have entered into the... Read More
Cipla’s JV with Jiangsu Acebright Pharma in China
Cipla, a Rs. 15,900 crore plus fourth largest Indian pharma company, has entered into a joint venture agreement with Jiangsu Acebright Pharmaceutical... Read More
Secarna enters co-development pact with MetP Pharma for transnasally delivered antisense oligonucleotide-based CNS therapeutics
Secarna Pharmaceuticals (Secarna), a new breed of biopharmaceutical company, has entered into a co-development agreement with MetP Pharma (MetP), a privately held... Read More
Case study – Alcon – Novartis Spin-Off: Alcon to become standalone Trading Company
Posted on04 Jul 2018
Comments0
Novartis AG intends to spinoff its ophthalmology division, Alcon, into a separately-traded standalone company. Preset: Novartis acquired Alcon in 2011. The Alcon... Read More
Sanofi and Lonza’s Strategic Partnership to Establish a Large-Scale Biologics Production Facility
Posted on28 Feb 2017
Comments0
Sanofi and Lonza announced today that they have entered into a strategic partnership to build and operate a large-scale mammalian cell culture... Read More